|
- What is the CAPOX (XELOX) chemotherapy regimen? - Drugs. com
The CAPOX regimen, also known as XELOX, is a combination chemotherapy protocol primarily used to treat advanced colorectal cancer, including colon and rectal cancers
- CAPOX - Wikipedia
CAPOX (also called XELOX[1]) is a chemotherapy regimen consisting of capecitabine (trade name Xeloda) combined with oxaliplatin [2][3] Xelox regime operates in 3-week cycles, usually with 8 cycles in total; Xeloda is taken orally twice daily for two weeks, while oxaliplatin is administered by IV on the first day of the cycle; there is a one
- CAPOX - NCI - National Cancer Institute
CAPOX is used to treat: Colorectal cancer that is advanced This combination may also be used with other drugs or treatments or to treat other types of cancer More About CAPOX Definition from the NCI Drug Dictionary - Detailed scientific definition and other names for this drug Important: The drug information on this page is meant to be
- CapOX (Xeloda + oxaliplatin)-Colon Cancer | ChemoExperts
How does capecitabine + oxaliplatin (CapOx) work? These drugs are designed to slow the growth and kill colon cancer by damaging the DNA of these rapidly dividing cells
- Oxaliplatin and capecitabine (CAPOX, XELOX) - Cancer Research UK
XELOX or CAPOX is a combination of chemotherapy drugs It is a treatment for bowel, oesophageal and stomach cancer Find out how you have it, possible side effects and other important information
- XELOX (or CAPOX) | Macmillan Cancer Support
XELOX (or CAPOX) is used to treat bowel cancer Learn more about how XELOX (CAPOX) is given, and its possible side effects
- Duration of Adjuvant Chemotherapy for Stage III Colon Cancer
For all the patients who received CAPOX, a therapy duration of 3 months of adjuvant therapy was noninferior to a duration of 6 months, independent of disease stage and risk group
- CAPOX Regimen Appears Noninferior to FOLFOX in Colorectal Cancer
In individuals with low-risk colon cancer (T1-3 and N1 disease), a 3-month regimen showed noninferiority vs a 6-month duration (HR, 1 01; 95% CI, 0 90-1 12), with 3-year disease-free survival (DFS) rates of 83 1% and 83 3%, respectively
|
|
|